We are pleased to announce the appointment of Paul Moraviec as Chairman of our Board of Directors

Paul Moraviec

– Brings decades of leadership experience in the Global MedTech sector

– As CEO of ConvaTec Group Plc, led the $5 billion IPO on the London Stock Exchange

– Transformed Abbott’s Diabetes Care EMEA division

BELGIUM – Ghent, May 12, 2021Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, is pleased to announce the appointment of Paul Moraviec as Chairman of its Board of Directors. 

Paul has amassed over three decades of global experience in the healthcare sector, having held multiple senior leadership positions. Most recently Paul led the ConvaTec Group Plc, a global medical products and technologies company, as Chief Executive Officer, orchestrating a successful company turnaround and subsequent $4.5 billion IPO on the London Stock Exchange in 2016, which at the time was the largest healthcare listing in Europe.

In addition, he brings highly relevant diabetes experience, having been Vice President of Abbott’s Diabetes Care International division between 2002 and 2007 where he transformed the EMEA business with low single digit growth and declining market share, to the fastest growing company in the glucose monitoring field.

Paul has also led the early-stage surgical robotics company Prosurgics, redesigning their product development and commercialisation strategy; and led a major restructuring and performance improvement program across UK, Germany and France for Johnson & Johnson’s Neuro Surgery business.

Paul will replace Harrold van Barlingen who will step down as Chairman and retain a seat on the Board as a Non-Executive Director.

 

Danaë Delbeke, CEO, Inventor and Co-founder of Indigo Diabetes, commented:

We’re thrilled to welcome Paul as Chairman of Indigo’s Board. His wealth of experience leading and transforming the businesses of MedTech companies will be invaluable as we continue to develop our subcutaneous continuous multi metabolite monitoring (‘CMM’) device. His appointment highlights our business potential and reflects Indigo’s ambition to make our device commercially available to people living with diabetes as soon as possible.

“We’d also like to extend our gratitude to our outgoing Chairman Harrold van Barlingen, who has made a significant contribution towards Indigo and our success thus far. We are grateful to retain his expertise as a board member.”

 

Paul Moraviec, Chairman of Indigo Diabetes, commented:

“I am delighted to be joining and chairing Indigo’s Board and look forward to helping the team successfully execute the strategy and guide the development of its CMM device, an innovative next generation approach to continuous monitoring of metabolites for people living with diabetes.”